Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Draft Genomes of 75 Vibrio Isolates from Retail Mollusks Collected in Canada between 2014 and 2018.

ABSTRACT: Vibrio spp. isolated from fresh retail mollusk samples were selected for sequencing based on their antimicrobial resistance burden. The de novo genomes include those for Vibrio alginolyticus (n = 48), V. diabolicus (n = 15), V. parahaemolyticus (n = 3), V. cholerae (n = 2), V. metoecus (n = 1), V. vulnificus (n = 1), V. fluvialis (n = 1), and unidentified Vibrio spp. (n = 4).

SUBMITTER: Teixeira JS

PROVIDER: S-EPMC9753667 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Draft Genomes of 75 Vibrio Isolates from Retail Mollusks Collected in Canada between 2014 and 2018.

Teixeira Januana S JS Dussault Forest F Hoover Emily E Shay Julie A JA Weedmark Kelly K Banerjee Swapan K SK

Microbiology resource announcements 20221109 12

Vibrio spp. isolated from fresh retail mollusk samples were selected for sequencing based on their antimicrobial resistance burden. The de novo genomes include those for Vibrio alginolyticus (n = 48), V. diabolicus (n = 15), V. parahaemolyticus (n = 3), V. cholerae (n = 2), V. metoecus (n = 1), V. vulnificus (n = 1), V. fluvialis (n = 1), and unidentified Vibrio spp. (n = 4). ...[more]

PMID: 36350157

Similar Datasets

Draft Genomes of 83 Vibrio Isolates from Fresh Canadian Mollusks.

Project description:A subset of Vibrio spp. isolated from fresh Canadian mollusks (2014 to 2018) were selected for sequencing based on antimicrobial resistance profiles. The resulting de novo draft genomes include 38 Vibrio alginolyticus, 32 V. diabolicus, 10 V. parahaemolyticus, 1 V. cholerae, 1 V. ordalii, and 1 Vibrio sp. isolate.

| S-EPMC9753734 | biostudies-literature

Draft Genome Sequences of Five Vibrio neptunius Strains Isolated from Hatcheries of Bivalve Mollusks.

Project description:Vibrio neptunius is a Gram-negative bacterium that has been shown to cause disease in marine bivalve mollusk larvae. Here, we report the draft genome sequences and annotations of five V. neptunius strains isolated from larvae of European oyster (Ostrea edulis) and Manila clam (Ruditapes philippinarum) at hatcheries in Galicia, northwest Spain.

| S-EPMC8086213 | biostudies-literature

Emergence of Vibrio cholerae O1 Sequence Type 75, South Africa, 2018-2020.

Project description:We describe the molecular epidemiology of cholera in South Africa during 2018-2020. Vibrio cholerae O1 sequence type (ST) 75 recently emerged and became more prevalent than the V. cholerae O1 biotype El Tor pandemic clone. ST75 isolates were found across large spatial and temporal distances, suggesting local ST75 spread.

| S-EPMC8544974 | biostudies-literature

Draft Genomes of 92 Vibrio Isolates from Warm-Water Shrimps Imported into Canada between 2009 and 2019.

Project description:Vibrio spp. were isolated from raw shrimps imported into Canada (2009 to 2019). A total of 92 isolates with various multidrug resistance profiles were sequenced, including 59 V. parahaemolyticus, 12 V. diabolicus, 10 V. cholerae, 7 V. alginolyticus, 1 V. campbellii, 1 V. harveyi, 1 V. owensii, and 1 V. vulnificus isolate.

| S-EPMC9753665 | biostudies-literature

Draft Genome Sequences of Four Vibrio parahaemolyticus Isolates from Clinical Cases in Canada.

Project description:Vibrio parahaemolyticus is a leading cause of bacterial gastroenteritis following ingestion of contaminated seafood. This report presents the draft genome sequences of four clinical strains of V. parahaemolyticus isolated in Canada. All four strains lack traditional pathogenic markers and possess uniquely individual characteristics identified using other typing criteria.

| S-EPMC4319507 | biostudies-literature

Time to market for drugs approved in Canada between 2014 and 2018: an observational study.

Project description:ObjectivesThis study examines the length of time between when a patent application is filed in Canada for a new drug and when it is available for patients (time to market) and various components of that time. It also looks at whether various factors explain the time between patent application to New Drug Submission (NDS) and compares Canadian and American times. Drugs approved between 1 January 2014 and 31 December 2018 are examined.DesignDescriptive study.Data sourcesWebsites from Health Canada, Food and Drug Administration, Merck Index, United States Patent and Trademark Office, WHO and previously published articles.InterventionsNone.Primary and secondary outcomesThe primary outcomes are time to market, time from patent application to NDS (pre-NDS time), review time, time from approval to availability (postapproval time) and factors that may influence the pre-NDS time. The secondary outcome is a comparison of Canadian and American review times and times between patent application and approval.ResultsThere were 113 drugs available for analysis. The median time to market was 11.80 years (IQR 9.40-14.05). The component median times were pre-NDS 10 years (IQR 8.05-12.80), review time 0.96 years (IQR 0.75-1.15) and postapproval time 0.15 years (IQR 0.08-0.28). Less than 8% of the pre-NDS time was explained by the factors that were analysed in a multiple linear regression equation. There was no statistically significant difference between Canadian and American pre-NDS times.ConclusionOnce a drug reaches the market, companies have a median of 8.2 years before the patent expires and generics can reach the market. Most of the time between the filing of a patent application and when a drug is marketed is determined by decisions that are largely under the control of the company.

| S-EPMC8258566 | biostudies-literature

mollusks

Project description:mollusks Raw sequence reads

| PRJNA306220 | ENA

Screening for Carbapenemases in Ertapenem-Resistant Enterobacteriaceae Collected at a Tunisian Hospital Between 2014 and 2018.

Project description:BackgroundCarbapenem-resistance is frequently detected in Enterobacteriaceae isolated from patients in Tunisia. The study was performed to identify frequent carbapenemases in Tunisian isolates.MethodsBetween May 2014 and January 2018, 197 ertapenem-resistant Enterobacteriaceae were isolated at the microbiological department of the Military Hospital of Tunis. The strains were phenotypically characterized and then subjected to in-house polymerase chain reaction (PCR) targeting the carbapenemase genes blaIMP, blaVIM, blaNDM, blaSPM, blaAIM, blaDIM,blaGIM, blaSIM, blaKPC, blaBIC , and blaOXA-48.ResultsThe assessed 197 ertapenem-resistant Enterobacteriaceae from Tunis comprised 170 Klebsiella pneumoniae, 19 Enterobacter cloacae, 6 Escherichia coli, 1 Citrobacter sedlakii, and 1 Enterobacter asburiae. Thereby, 55 out of 197 isolates (27.9%) were from blood cultures, suggesting a systemic disease. The carbapenemase gene blaOXA-48 quantitatively dominated by far with 153 detections, followed by blaNDM with 14 detections, which were distributed about the whole study interval. In contrast, blaBIC and blaVIM were only infrequently identified in 5 and 3 cases, respectively, while the other carbapenamases were not observed.ConclusionsThe carbapenemase gene blaOXA-48 was identified in the vast majority of ertapenem-resistant Tunisian Enterobacteriaceae while all other assessed carbapenemases were much less abundant. In a quantitatively relevant minority of isolates, the applied PCR-based screening approach did not identify any carbapenemases.

| S-EPMC6444801 | biostudies-literature

Characterization of VCC-1, a Novel Ambler Class A Carbapenemase from Vibrio cholerae Isolated from Imported Retail Shrimp Sold in Canada.

Project description:One of the core goals of the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) is to monitor major meat commodities for antimicrobial resistance. Targeted studies with methodologies based on core surveillance protocols are used to examine other foods, e.g., seafood, for antimicrobial resistance to detect resistances of concern to public health. Here we report the discovery of a novel Ambler class A carbapenemase that was identified in a nontoxigenic strain of Vibrio cholerae (N14-02106) isolated from shrimp that was sold for human consumption in Canada. V. cholerae N14-02106 was resistant to penicillins, carbapenems, and monobactam antibiotics; however, PCR did not detect common β-lactamases. Bioinformatic analysis of the whole-genome sequence of V. cholerae N14-02106 revealed on the large chromosome a novel carbapenemase (referred to here as VCC-1, for Vibrio cholerae carbapenemase 1) with sequence similarity to class A enzymes. Two copies of blaVCC-1 separated and flanked by ISVch9 (i.e., 3 copies of ISVch9) were found in an acquired 8.5-kb region inserted into a VrgG family protein gene. Cloned blaVCC-1 conferred a β-lactam resistance profile similar to that in V. cholerae N14-02106 when it was transformed into a susceptible laboratory strain of Escherichia coli. Purified VCC-1 was found to hydrolyze penicillins, 1st-generation cephalosporins, aztreonam, and carbapenems, whereas 2nd- and 3rd-generation cephalosporins were poor substrates. Using nitrocefin as a reporter substrate, VCC-1 was moderately inhibited by clavulanic acid and tazobactam but not EDTA. In this report, we present the discovery of a novel class A carbapenemase from the food supply.

| S-EPMC4775928 | biostudies-literature

Draft Genome Sequencing of Vibrio cholerae O1 El Tor Isolates Collected in the Russian Federation from Imported Cholera Cases.

Project description:We report the draft genome sequencing of five Vibrio cholerae O1 El Tor clinical isolates collected in the Russian Federation from imported cholera cases in 2006, 2010, and 2012. In the initial phylogenetic analysis, one isolate clustered with the Haiti/Nepal-4 group.

| S-EPMC4102861 | biostudies-literature